Pharma Roche feels more biosimilar pain as exec pulls back expectations for Tecentriq in early lung cancer
Roche is feeling the pain as stated in the above article. Below is an excerpt from the article above:
Once Roche’s top three best-selling drugs, Avastin, Herceptin and Rituxan have descended on Roche’s sales charts. They now rank third, sixth and seventh on the company's list of best-selling medicines, respectively.
Avastin sales during the quarter plummeted 42% to CHF 863 million, while Herceptin dropped 37% year over year to CHF 755 million. Rituxan sales fell by nearly half to CHF 705 million.
Roche will need to do something if they want to regain their market share. The drop in revenue is no chicken feed either.
Media Thread, page-1026
-
- There are more pages in this discussion • 14,817 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.9¢ |
Change
-0.004(7.55%) |
Mkt cap ! $364.4M | |||
| Open | High | Low | Value | Volume |
| 5.3¢ | 5.3¢ | 4.9¢ | $1.061M | 21.17M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 52 | 6583733 | 4.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.1¢ | 1287081 | 5 |
View Market Depth
| Last trade - 16.10pm 15/10/2024 (20 minute delay) ? |
| IMU (ASX) Chart |